Suppr超能文献

局部复发切除后中高危非转移性肾细胞癌:ASSURE(ECOG-ACRIN E2805)辅助试验的解剖分类和分析。

Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.

机构信息

Fox Chase Cancer Center-Temple Health System, Philadelphia, Pennsylvania.

ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, Massachusetts.

出版信息

J Urol. 2020 Apr;203(4):684-689. doi: 10.1097/JU.0000000000000588. Epub 2019 Oct 9.

Abstract

PURPOSE

We describe what is to our knowledge a novel classification system for local recurrence after surgery of renal cell carcinoma. We assessed its prognostic implications using prospective, randomized controlled data.

MATERIALS AND METHODS

We queried the ASSURE (Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery) (ECOG-ACRIN [Eastern Cooperative Oncology Group-American College of Radiology Imaging Network] E2805) trial data for patients with fully resected, intermediate-high risk, nonmetastatic renal cell carcinoma with local recurrence. We used certain definitions, including type I-single recurrence in a remnant kidney or ipsilateral renal fossa, type II-single recurrence in the ipsilateral vasculature, the ipsilateral adrenal gland or a lymph node, type III-single recurrence in other intra-abdominal soft tissues or organs and type IV-any combination of types I-III or multiple recurrences of a single type. Multivariable logistic regression and the log rank test were performed to identify clinicopathological predictors and compare survival, respectively.

RESULTS

Of the 1,943 patients 300 (15.4%) had local recurrence, which was type I, II, III and IV in 66 (22.0%), 97 (32.3%), 87 (29.0%) and 50 (16.7%), respectively. Surgical modality (minimally invasive vs open) and type of surgery (partial vs radical) did not predict any local recurrence. Five-year cancer specific survival and overall survival were worse in patients with type IV recurrence (each p <0.001). There was no difference in survival among patients with types I to III recurrence.

CONCLUSIONS

In patients with intermediate-high risk nonmetastatic renal cell carcinoma local recurrence appears to be a function of biology more than of surgical modality or surgery type. The prognosis for solitary intra-abdominal local recurrences appear similar regardless of location (types I-III). Local recurrences involving multiple sites and/or subdivisions are associated with worse survival (type IV).

摘要

目的

我们描述了一种新颖的肾细胞癌手术后局部复发分类系统,这在我们的认知范围内尚属首次。我们使用前瞻性、随机对照数据评估了该分类系统的预后意义。

材料与方法

我们查询了 ASSURE(苹果酸舒尼替尼或索拉非尼甲苯磺酸盐治疗手术切除的肾癌患者)(ECOG-ACRIN [东部肿瘤协作组-美国放射肿瘤学会影像学网络] E2805)试验数据,以确定完全切除、中高危、无远处转移且局部复发的肾细胞癌患者。我们使用了特定的定义,包括 I 型——残肾或同侧肾窝单发复发、II 型——同侧血管、同侧肾上腺或淋巴结单发复发、III 型——其他腹腔内软组织或器官单发复发和 IV 型——任何类型 I-III 的组合或同一类型的多次复发。我们分别使用多变量逻辑回归和对数秩检验来确定临床病理预测因素和比较生存情况。

结果

在 1943 例患者中,有 300 例(15.4%)发生局部复发,其中 I 型、II 型、III 型和 IV 型分别为 66 例(22.0%)、97 例(32.3%)、87 例(29.0%)和 50 例(16.7%)。手术方式(微创与开放)和手术类型(部分与根治)均不能预测任何局部复发。IV 型复发患者的 5 年癌症特异性生存率和总生存率均较差(均<0.001)。I 至 III 型复发患者的生存率无差异。

结论

在中高危、无远处转移的肾细胞癌患者中,局部复发似乎是生物学因素的结果,而不是手术方式或手术类型的结果。孤立性腹腔内局部复发的预后似乎与位置无关(I 至 III 型)。涉及多个部位和/或亚区的局部复发与较差的生存率相关(IV 型)。

相似文献

引用本文的文献

1
Percutaneous cryoablation of kidney tumors after partial nephrectomy.肾部分切除术后肾肿瘤的经皮冷冻消融术。
Wideochir Inne Tech Maloinwazyjne. 2024 Oct 25;19(4):483-488. doi: 10.20452/wiitm.2024.17904. eCollection 2024 Dec 27.
7
Outcomes for Atypical Tumor Recurrences Following Minimally Invasive Kidney Cancer Operations.微创肾癌手术后非典型肿瘤复发的结局
Eur Urol Open Sci. 2022 May 6;40:125-132. doi: 10.1016/j.euros.2022.04.005. eCollection 2022 Jun.

本文引用的文献

5
Renal Mass and Localized Renal Cancer: AUA Guideline.肾脏肿块和局限性肾细胞癌:AUA 指南。
J Urol. 2017 Sep;198(3):520-529. doi: 10.1016/j.juro.2017.04.100. Epub 2017 May 4.
10
EAU guidelines on renal cell carcinoma: 2014 update.EAU 指南:肾细胞癌. 2014 年更新版.
Eur Urol. 2015 May;67(5):913-24. doi: 10.1016/j.eururo.2015.01.005. Epub 2015 Jan 21.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验